BridgeMD
Prevention of opioid-induced constipation in patients with advanced cancer.
EU CTIS ID: 2023-509462-38-00
What this study is testing
In patients with advanced cancer, starting with opioids for pain: To prove non-inferiority of magnesium hydroxide to macrogol/electrolytes in the prevention of OIC, based on the percentage of patients without constipation (BFI-score <30) after 14 days of treatment.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- In order to be eligible to participate in this study, a subject must meet all of the following criteria: Patients with advanced cancer (≥18 years);
- Starting with slow release or transdermal opioids for pain;
- Able to complete a Dutch questionnaire.
You likely can't join if
- A potential subject who meets any of the following criteria will be excluded from participation in this study: Patients with contra-indications for laxatives;
- Maintenance treatment with laxatives during the last two weeks
- Severely impaired renal function (serum creatinine >180 umol/l);
- Diarrhea at the start of the study, defined as the passage of three or more loose or liquid stools per day (or more frequent passage than is normal for the individual).
- Life expectancy < 1 month
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.